OPKO Health, Inc.

OPKO Health, Inc.

OPKNYSE / NASDAQHealthcareSmall cap

$1.57-$0.04 (-2.5%)

Last close · Data as of Nov 20, 2026

Market cap
$1.1B
P/E
-4.9x
EV / EBITDA
-27.4x
Revenue
$606.9M
Net margin
-37.2%
ROCE
-8.2%

+20.8% over the last year

OPKO Health, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-5.4%
3M
+7.5%
6M
+27.6%
1Y
+20.8%
5Y
-63.9%

52-week range

Day change -$0.04 (-2.5%) from $1.61 to $1.57 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in OPK, bought on each weekday since 2021.

News & filings

What OPKO Health filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 226 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 3.97 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics.

Read moreShow less

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Sector
Healthcare
Shares outstanding
759.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.1B
P/E
-4.9x
P/B
0.9x
EV / EBITDA
-27.4x
EV / Sales
1.9x
P/S
1.8x
52-week high
$1.77
52-week low
$1.10

Profitability

Operating margin
-19.3%
Net margin
-37.2%
EBITDA margin
-6.8%
ROE
-17.8%
ROCE
-8.2%
ROIC
-8.1%
ROA
-11.7%
Asset turnover
0.31

Growth

Revenue
$606.9M
Revenue growth, 1Y
-14.9%
Revenue CAGR, 3Y
-15.5%
Net profit growth, 1Y
324.0%
Free cash flow
-$190.8M

Solvency

Current ratio
3.97
Debt / Equity
0.31
Debt / Assets
0.21
CFO / Net profit
0.79
Cash / Market cap
33.5%

Where the revenue went

Some FY2025 lines are not reported, so the ones that are appear as a table.

LineFY2025
Revenue$606.9M
Cost of revenue$400.9M
Gross profit$205.9M
Operating expenses—
Research and development$124.0M
Selling, general and administrative$223.0M
Pretax income-$241.4M
Tax and other-$15.7M
Net income-$225.7M

Revenue and net profit

Revenue fell 14.9% in FY2025; net profit is the dashed line.

OPKO Health, Inc. revenue and net profit by fiscal year
OPKO Health, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.0B-$328.4M
FY2023$863.5M-$188.9M
FY2024$713.1M-$53.2M
FY2025$606.9M-$225.7M

Cash flows

FY2025: -$178.5M from operations, -$190.8M free after investment (dashed).

OPKO Health, Inc. operating and free cash flow by fiscal year
OPKO Health, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$95.2M-$119.8M
FY2023-$28.2M-$44.5M
FY2024-$183.5M-$208.5M
FY2025-$178.5M-$190.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$606.9M-14.9%1Y
EBITDA
-$41.3M-130.5%1Y
Net profit
-$225.7M
Cash from operations
-$178.5M
Free cash flow
-$190.8M
Revenue CAGR, 3Y
-15.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$606.9M-$41.3M-$225.7M-$190.8M-17.8%-14.9%+324.0%

Monthly returns

Month-by-month returns of OPK across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.9B
Liabilities$664.0M
Equity$1.3B
Paid-in capital$3.6B
Retained earnings-$2.3B
Treasury stock$3.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; OPK highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. OPKO Health, Inc. (this company)1.9x

Not shown (no positive earnings and no EV / Sales): Savara Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
OPKO Health, Inc.OPKthis company$1.1B-4.9x0.9x-17.8%-27.4x
Absci CorporationABSI$1.1B-9.9x6.0x-60.8%-10.9x
Aktis Oncology, Inc.AKTS$1.1B-17.3x-7.5x43.6%-14.8x
MannKind CorporationMNKD$1.1B185.5x-21.3x-11.5%26.8x
Savara Inc.SVRA$1.1B-9.1x5.3x-58.5%-8.8x
Omada Health, Inc.OMDA$1.1B-84.7x4.7x-5.6%-181.0x
Xeris Biopharma Holdings, Inc.XERS$1.1B1916.5x77.6x4.0%28.6x
Collegium Pharmaceutical, Inc.COLL$1.1B16.9x3.5x20.8%4.1x
CONMED CorporationCNMD$1.1B22.5x1.0x4.6%10.5x
Peer median—3.9x4.1x-0.8%-2.4x

Year-to-date ROI

OPK since 1 January, against earlier years.

Historical volatility

OPK's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Cost of revenueCost Of Revenue$400.9M
Gross profitGross Profit$205.9M
Operating expensesOperating Expense$424.9M
Research and developmentResearch And Development$124.0M
Selling, general and administrativeSelling General And Administration$223.0M
Depreciation and amortisationDepreciation And Amortization In Income Statement$77.9M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$77.9M
Amortization$77.9M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$77.9M
Total expensesTotal Expenses$825.9M
Pretax incomePretax Income-$241.4M

Learn while you research

Academy chapters picked for OPKO Health, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →